8-K Announcements
6Material company update
May 22, 2026·SEC
Material company update
Mar 17, 2026·SEC
Material company update
Mar 2, 2026·SEC
Akari Therapeutics, Plc(AKTX)Earnings, Financials & Key Ratios
AKTX•NASDAQ
$9.69
Price updated Jun 30, 2026
AboutAkari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.Show more
- Revenue$0
- EBITDA-$17M+19.8%
- Net Income-$17M+12.6%
- EPS (Diluted)-20800.00+84.3%
- ROE-68.43%+62.0%
AKTX Price & Volume
Akari Therapeutics, Plc (AKTX) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Threatens Operational Liquidity Sustainability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
Key Thesis Takeaways
- Akari Therapeutics operates as a pre-revenue biotechnology firm characterized by significant R&D-driven cash burn and a lack of meaningful operating leverage.
- The company's reliance on external financing to sustain clinical development, coupled with an accumulated deficit of $279.0 million, presents substantial risks to long-term shareholder value.
- Investors should monitor the firm's ability to secure additional capital, as the current liquidity position appears insufficient to support ongoing operations without further dilutive events.
Verdict Logic
the company's precarious liquidity position, highlighted by a cash balance of only $2.8 million against immediate obligations, suggests a high risk of near-term insolvency or significant shareholder dilution.
AKTX Growth Metrics
Akari Therapeutics, Plc (AKTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-56.43%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM47.23%
Return on Capital
10 Years-404.54%
5 Years-641.08%
3 Years-782.11%
Last Year-52.2%
AKTX Recent Earnings
Akari Therapeutics, Plc (AKTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (30%)
Q2 2026Latest
May 19, 2026Metric
Actual
Est
EPS
$688.00-51629.3%
$1.33
Rev
—
—
Q2 2026
Apr 7, 2026Metric
Actual
Est
EPS
$2.99-66.1%
$1.80
Rev
—
—
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.10-150.0%
$0.04
Rev
—
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.06+33.3%
$0.09
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 19, 2026 | $688.00vs $1.33-51629.3% | — |
| Q2 2026 | Apr 7, 2026 | $2.99vs $1.80-66.1% | — |
| Q4 2025 | Nov 13, 2025 | $0.10vs $0.04-150.0% | — |
| Q3 2025 | Aug 13, 2025 | $0.06vs $0.09+33.3% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Akari Therapeutics, Plc (AKTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $9.69 | $203.88K | -0.00 | — | — | -68.43% | — | |
| $2.20 | $119.3M | -1.16 | — | — | -124.06% | — | |
| $14.48 | $1.22B | -27.32 | — | — | -38.92% | — | |
| $113.28 | $5.47B | 17.90 | 5.91% | 32.63% | 49.18% | — | |
| $23.14 | $1.71B | 7.01 | 18.52% | 118.91% | 47.59% | — | |
| $5.23 | $1.28B | -20.12 | 22.09% | -13.58% | -38.11% | — |
Compare AKTX vs Peers
Akari Therapeutics, Plc (AKTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AKTX SEC Filings & Documents
Akari Therapeutics, Plc (AKTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when AKTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AKTX Frequently Asked Questions
Akari Therapeutics, Plc (AKTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is AKTX profitable?
Akari Therapeutics, Plc (AKTX) reported a net loss of $28.0M for fiscal year 2025.
Dividend & Returns
What is AKTX's return on equity?
Akari Therapeutics, Plc (AKTX) has a return on equity (ROE) of -68.4%. Negative ROE indicates the company is unprofitable.
What is Akari Therapeutics, Plc's free cash flow?
Akari Therapeutics, Plc (AKTX) had negative free cash flow of $10.9M in fiscal year 2025, likely due to heavy capital investments.